Cipla Facing Damages After India Upholds Erlotinib Patent
This article was originally published in PharmAsia News
Executive Summary
Now that a long running patent-related case in India concerning Roche's anticancer, Tarceva (erlotinib), has gone the Swiss multinational's way, challenger Cipla is left staring at the prospect of paying damages.